trichlorfon has been researched along with Acute Confusional Senile Dementia in 47 studies
Trichlorfon: An organochlorophosphate cholinesterase inhibitor that is used as an insecticide for the control of flies and roaches. It is also used in anthelmintic compositions for animals. (From Merck, 11th ed)
trichlorfon : A phosphonic ester that is dimethyl phosphonate in which the hydrogen atom attched to the phosphorous is substituted by a 2,2,2-trichloro-1-hydroxyethyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Most adverse events were mild to moderate in intensity, gastrointestinal in nature, and transient." | 2.69 | Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease. ( Ashford, JW; Bieber, F; Gulanski, B; Lettieri, J; Markesbery, WR; Mas, J; Orazem, J; Pettigrew, LC; Ruzicka, BB; Schmitt, FA; Smith, CD; Tikhtman, AJ; Wekstein, DR; Wermeling, DP, 1998) |
| " A pilot study, and Phase I and Phase II studies of metrifonate in Alzheimer's disease (AD) patients conducted prior to the current study showed benign, dose-dependent adverse event profiles consisting primarily of gastrointestinal events, optimal daily dosing with a loading phase (in the absence of a loading dose phase, 6-8 weeks were required to attain steady-state AChE inhibition levels), and an improvement in Alzheimer's Disease Assessment Scale (ADAS) scores." | 2.69 | Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study. ( Bieber, F; Cutler, NR; Cyrus, P; Gulanski, B; Jhee, SS; Sramek, JJ; TanPiengco, P, 1998) |
| "Primary efficacy variables were the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and the Clinician's Interview-Based Impression of Change with Caregiver Input (CIBIC-plus)." | 2.69 | Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. ( Bieber, F; Cyrus, PA; Gulanski, B; Mas, J; Morris, JC; Orazem, J; Ruzicka, BB, 1998) |
| " Safety was assessed by the prevalence of premature study termination and treatment-emergent adverse events, as well as by changes in vital signs, findings on electrocardiographic and neurologic examinations, and abnormalities on laboratory tests." | 2.69 | Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group. ( Cyrus, PA; Eisner, LS; Griffin, T; Gulanski, B; Jann, MW; Margolin, DI, 1999) |
| "Metrifonate significantly improved a wide range of symptoms across all four clinical domains of AD in a dose-dependent manner, and was safe and well tolerated at both doses studied." | 2.69 | A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study. ( Collins, O; Dubois, B; McKeith, I; Meulien, D; Orgogozo, JM, 1999) |
| "Development of neuropathology in Alzheimer's disease (AD) cannot be studied directly in living patients." | 2.69 | Effects of time and cholinesterase inhibitor treatment on multiple cerebrospinal fluid parameters in Alzheimer's disease. ( Becker, RE; Galasko, D; Markwell, S; Moriearty, PL; Seubert, P; Unni, L; Vicari, S, 1999) |
| " We dosed metrifonate to achieve a 40-60% inhibition of red blood cell acetylcholinesterase activity." | 2.68 | Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease. ( Becker, RE; Colliver, JA; Markwell, SJ; Moriearty, PL; Unni, LK; Vicari, S, 1996) |
| " In order to maximize and prolong positive drug effects, it is important to start early and adjust dosage during the treatment." | 2.41 | Cholinesterase inhibitors stabilize Alzheimer's disease. ( Giacobini, E, 2000) |
| "Metrifonate, at therapeutic doses for Alzheimer's disease, achieves high levels of cholinesterase inhibition, i." | 2.40 | The pharmacological basis for metrifonate's favourable tolerability in the treatment of Alzheimer's disease. ( Heinig, R; Schmidt, BH, 1998) |
| "Trichlorfon is a specific inhibitor of cholinesterases." | 1.35 | In vitro reactivation of trichlorfon-inhibited butyrylcholinesterase using HI-6, obidoxime, pralidoxime and K048. ( Jun, D; Kuca, K; Pohanka, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 31 (65.96) | 18.2507 |
| 2000's | 16 (34.04) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pohanka, M | 1 |
| Jun, D | 1 |
| Kuca, K | 1 |
| Becker, RE | 6 |
| Unni, LK | 4 |
| Greig, NH | 1 |
| Rakonczay, Z | 2 |
| López-Arrieta, JM | 1 |
| Schneider, L | 1 |
| Womack, C | 1 |
| Hannant, ME | 1 |
| Colliver, JA | 3 |
| Markwell, SJ | 2 |
| Moriearty, PL | 4 |
| Vicari, S | 3 |
| Schneider, LS | 3 |
| Scali, C | 1 |
| Giovannini, MG | 1 |
| Bartolini, L | 1 |
| Prosperi, C | 1 |
| Hinz, V | 1 |
| Schmidt, B | 1 |
| Pepeu, G | 1 |
| Lamb, HM | 1 |
| Faulds, D | 1 |
| Giacobini, E | 2 |
| Taylor, P | 1 |
| Pettigrew, LC | 1 |
| Bieber, F | 4 |
| Lettieri, J | 1 |
| Wermeling, DP | 1 |
| Schmitt, FA | 1 |
| Tikhtman, AJ | 1 |
| Ashford, JW | 1 |
| Smith, CD | 1 |
| Wekstein, DR | 1 |
| Markesbery, WR | 1 |
| Orazem, J | 3 |
| Ruzicka, BB | 3 |
| Mas, J | 3 |
| Gulanski, B | 6 |
| Cutler, NR | 1 |
| Jhee, SS | 1 |
| Cyrus, P | 1 |
| TanPiengco, P | 1 |
| Sramek, JJ | 1 |
| Knopman, DS | 1 |
| Cummings, JL | 5 |
| Cyrus, PA | 7 |
| Morris, JC | 1 |
| McKeith, IG | 1 |
| Kaufer, D | 1 |
| Schmidt, BH | 1 |
| Heinig, R | 1 |
| Peskind, ER | 1 |
| Tariot, PN | 1 |
| Oberpichler-Schwenk, H | 1 |
| Zamar, AC | 1 |
| Wise, ME | 1 |
| Watson, JP | 1 |
| Terpstra, T | 2 |
| Sandson, TA | 1 |
| Jann, MW | 1 |
| Eisner, LS | 1 |
| Margolin, DI | 1 |
| Griffin, T | 1 |
| Williams, BR | 1 |
| Raskind, MA | 1 |
| Gulanski, BI | 1 |
| Dubois, B | 2 |
| McKeith, I | 2 |
| Orgogozo, JM | 1 |
| Collins, O | 1 |
| Meulien, D | 1 |
| Ringman, JM | 1 |
| Seubert, P | 1 |
| Galasko, D | 1 |
| Markwell, S | 1 |
| Unni, L | 1 |
| Farlow, MR | 1 |
| Nadel, A | 2 |
| Lahiri, DK | 1 |
| Brashear, A | 1 |
| Shikiar, R | 1 |
| Shakespeare, A | 1 |
| Sagnier, PP | 1 |
| Wilkinson, D | 1 |
| Dartigues, JF | 1 |
| Gélinas, I | 1 |
| Gauthier, S | 1 |
| Pakaski, M | 1 |
| Fakla, I | 1 |
| Papp, H | 1 |
| Kasa, P | 1 |
| Mega, MS | 2 |
| Dinov, ID | 2 |
| Lee, L | 1 |
| O'Connor, SM | 2 |
| Masterman, DM | 1 |
| Wilen, B | 1 |
| Mishkin, F | 1 |
| Toga, AW | 2 |
| Takeda, M | 1 |
| Shinosaki, K | 1 |
| Nishikawa, T | 1 |
| Tanaka, T | 1 |
| Kudo, T | 1 |
| Nakamura, Y | 1 |
| Kashiwagi, Y | 1 |
| Reback, E | 1 |
| Felix, J | 1 |
| Masterman, DL | 1 |
| Phelps, ME | 1 |
| Small, GW | 1 |
| Masterman, D | 1 |
| Schreiter Gasser, U | 1 |
| Gasser, T | 1 |
| Liu, L | 1 |
| Ikonen, S | 1 |
| Heikkinen, T | 1 |
| Tapiola, T | 1 |
| van Groen, T | 1 |
| Tanila, H | 1 |
| Womack, CL | 1 |
| Dick, BW | 1 |
| Robbs, RS | 1 |
13 reviews available for trichlorfon and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Resurrecting clinical pharmacology as a context for Alzheimer disease drug development.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials as Topi | 2009 |
Metrifonate for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Nootropic Agents; Randomized Controlled Trials | 2006 |
New therapeutic approaches to Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Carbamates; Cholinergic Agents; Cholinesterase Inhibitors; Cognitio | 1996 |
Metrifonate.
Topics: Administration, Oral; Alzheimer Disease; Animals; Avoidance Learning; Brain; Cholinesterase Inhibito | 1997 |
Metrifonate. A viewpoint.
Topics: Acetylcholine; Alzheimer Disease; Animals; Anthelmintics; Cerebral Cortex; Cholinesterase Inhibitors | 1997 |
The pharmacological basis for metrifonate's favourable tolerability in the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Trichlorfon | 1998 |
Pharmacologic approaches to cognitive deficits in Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Diso | 1998 |
Evaluating response to metrifonate.
Topics: Administration, Oral; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dose-R | 1998 |
New therapeutic approaches to cognitive impairment.
Topics: Aged; Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; D | 1998 |
Metrifonate: a new agent for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinergic Agonists; Cholinesterase Inhibitors; Humans; Trichlorfon | 1999 |
Metrifonate: update on a new antidementia agent.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders | 1999 |
Cholinesterase inhibitors stabilize Alzheimer's disease.
Topics: Alzheimer Disease; Brain; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition | 2000 |
[A comparison of cholinesterase inhibitors and ginkgo extract in treatment of Alzheimer dementia].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Double | 2001 |
18 trials available for trichlorfon and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Female; Humans; Male; Middle Aged; Pr | 1996 |
Effects of metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-controlled, 6-month study.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Female | 1998 |
Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cholinesterase Inhibitors; | 1998 |
Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Dose-Response | 1998 |
Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group.
Topics: Aged; Alzheimer Disease; Behavior; Cholinesterase Inhibitors; Cognition Disorders; Dose-Response Rel | 1998 |
Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavior; Cholinesterase Inhibitors; Cognition Disorders | 1998 |
The clinical trial protocol of the Metrifonate in Alzheimer's Trial (MALT).
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Female; France; Humans; Male; Psychia | 1998 |
Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Double-Blind Method; Humans; Parasympathetic Ner | 1998 |
Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Double- | 1999 |
The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; | 1999 |
A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; D | 1999 |
Effects of time and cholinesterase inhibitor treatment on multiple cerebrospinal fluid parameters in Alzheimer's disease.
Topics: Aged; alpha 1-Antichymotrypsin; Alzheimer Disease; Amyloid beta-Peptides; Apolipoproteins E; Biomark | 1999 |
Metrifonate treatment of AD: influence of APOE genotype.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; Dose-Respo | 1999 |
The impact of metrifonate therapy on caregivers of patients with Alzheimer's disease: results from the MALT clinical trial. Metrifonate in Alzheimer's Disease Trial.
Topics: Aged; Alzheimer Disease; Analysis of Variance; Caregivers; Chi-Square Distribution; Cholinesterase I | 2000 |
Metrifonate enhances the ability of Alzheimer's disease patients to initiate, organize, and execute instrumental and basic activities of daily living.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; D | 2000 |
Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Behavior; Cerebrovascular Circulation; Cholinesterase Inhibitors; Double-Bl | 2000 |
Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Cognition Disorders; F | 2001 |
Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Anxiety; Apolipoproteins E; Behavi | 2001 |
16 other studies available for trichlorfon and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
In vitro reactivation of trichlorfon-inhibited butyrylcholinesterase using HI-6, obidoxime, pralidoxime and K048.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Cholinest | 2009 |
Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
Topics: Acetylcholinesterase; Alzheimer Disease; Benzazepines; Brain; Butyrylcholinesterase; Carbamates; Cer | 2003 |
Pharmacokinetics and pharmacodynamics of metrifonate in humans.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterases; Chromatography, H | 1994 |
Effect of metrifonate on extracellular brain acetylcholine and object recognition in aged rats.
Topics: Acetylcholine; Administration, Oral; Aging; Alzheimer Disease; Animals; Brain; Cerebral Cortex; Chol | 1997 |
Metrifonate. A viewpoint.
Topics: Alzheimer Disease; Anthelmintics; Binding Sites; Cholinesterase Inhibitors; Humans; Schistosomiasis; | 1997 |
Metrifonate for Alzheimer's disease: is the next cholinesterase inhibitor better?
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Randomized Controlled Trials as Topic; Trichlo | 1998 |
[Alzheimer disease. Irreversible AChE inhibition with metrifonate].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Prodrugs; Trichlorfon | 1998 |
New drug treatment for Alzheimer's disease. Treatment with metrifonate warrants multicentre trials.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Humans; Indans; M | 1998 |
Treating Alzheimer's disease with cholinergic drugs, Part 2.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Piperidines; Trichlorfon | 1999 |
Metrifonate for Alzheimer's disease: is the next cholinesterase inhibitor better?
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Trichlorfon | 1999 |
In vitro effects of metrifonate on neuronal amyloid precursor protein processing and protein kinase C level.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Basal Nucleus of M | 2000 |
Metrifonate for Alzheimer's disease patients.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Humans; | 2000 |
Alzheimer's disease: translating neurochemical insights into clinical benefits.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Humans; Magnetic Reso | 2000 |
[Treatment of the elderly dementia patients].
Topics: Aged; Alzheimer Disease; Benzazepines; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; In | 2000 |
The effects of long-term treatment with metrifonate, a cholinesterase inhibitor, on cholinergic activity, amyloid pathology, and cognitive function in APP and PS1 doubly transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cholinesterase Inhibitors; Cognition; Dise | 2002 |
Stability of peripheral hematological parameters after chronic acetylcholinesterase inhibition in man.
Topics: Alzheimer Disease; Blood Cell Count; Cholinesterase Inhibitors; Hemoglobins; Humans; Leukocyte Count | 1991 |